ClinicalTrials.gg
RecruitingNCT07424027Updated Feb 20, 2026

Central Vein Sign in Multiple Sclerosis Extension Study

An interventional study of MRI Contrast in Multiple Sclerosis, sponsored by The Cleveland Clinic. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Multiple Sclerosis by The Cleveland Clinic — 1 open to participants now, 2 under way, none of them phase 3. Multiple Sclerosis · The Cleveland Clinic.

Planned enrollment
2nd of 11
40 · median 24
Started
2025
the only one that year
No phase
9 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Multiple Sclerosis by The Cleveland Clinic, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 13th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 13 studies in Multiple Sclerosis by The Cleveland Clinic is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Multiple Sclerosis by The Cleveland Clinic, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and evaluation of treatment response for MS. The central vein sign (CVS) and the paramagnetic rim lesion (PRL) are two biomarkers that have shown promise in improving diagnostic accuracy for MS.

The goal of this study is to provide pilot information on the long-term performance of the CVS and PRL to help diagnose and follow people with MS. The study will follow 40 participants over 48 months to determine if the CVS and PRL help make a diagnosis of MS and how they can be used to follow people with MS. The study will also examine how PRL and CVS change over 48 months. The results of this pilot study will inform the development of a grant application to extend 5-year follow-up for all 420 participants of the CAVS-MS study. The study will use high-resolution T2*-weighted MRI to detect the CVS and PRLs. An MRI of the brain with contrast will be used to examine CVS, PRL and longitudinal analysis of lesions that slowly grow over time (slowly expanding lesions [SELs]). The results of this study have the potential to improve the accuracy of diagnosing and treating MS.

Read the detailed description

The goal of this study is to provide pilot information on the long-term diagnostic and prognostic performance of the CVS and PRL. This study will be leveraged on the Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS)" (IRB 20-063) which is an NIH-supported (1U01NS116776-01), 2-year, prospective, international, multicenter study conducted by the North American Imaging in MS Cooperative (NAIMS) to evaluate CVS as an MRI-based diagnostic biomarker for immediate translation into clinical care. This study will extend follow-up in a pilot study of 3 sites to confirm the diagnostic performance of the CVS and PLR at 4-year follow-up and explore the prognostic value of PRLs in those with MS at 4 years.

The CVS is proposed as a diagnostic biomarker with improved sensitivity for a diagnosis of MS, while retaining diagnostic specificity - all in an-easy-to use diagnostic test that can be applied in patients with both typical and atypical disease presentation. There is extensive research demonstrating the ability of the CVS criteria to discriminate MS lesions from common mimickers, such as vascular disease and migraine. However, the CVS has mainly been applied in cross-sectional studies. In addition, the majority of these studies have focused analysis primarily on patients presenting with typical clinical events of demyelination (i.e. a classic CIS). This study will evaluate CVS criteria prospectively in individuals with typical and atypical MS presentations. In Aim 1, we will examine sensitivity and specificity of CVS criteria in conjunction with, and in comparison to, the McDonald Criteria. In Aim 2, we will examine CVS in a population where McDonald criteria explicitly cannot be applied. Because the likelihood of MS is lower in this group, we will focus on specificity, which is where the unmet need exists.

Although current MS diagnostic criteria are sensitive in most typical cases, the use of the CVS may hasten diagnosis in patients with low lesion numbers and those without dissemination in time. In the past, studies that informed revision of the diagnostic criteria used "clinically definite MS" (defined as two separate clinical events) as the definitive determination of a diagnosis. In the current treatment era, however, clinically definite MS is less relevant, since most patients will be diagnosed after a first clinical event (relapse) and will go on to start treatment prior to even having a second relapse. For this reason, we will use the 2017 McDonald Criteria as the "gold standard" for our proposed study.

Importantly, in the current study the CVS will be applied in a population where the McDonald Criteria are not applicable (atypical presentations) and where currently a significant unmet clinical need exists. Because the studies that informed the diagnostic criteria did not include patients presenting with atypical syndromes, such patients are not covered in the McDonald Criteria path, but are frequently given a diagnosis of MS on the basis of MRI findings. To address this limitation, we will examine the presence of CVS as a predictor of development of future clinical events, within a 24-month period, that would satisfy the 2017 McDonald Criteria. Thus, the results of this study will have a significant impact on both improving sensitivity in those presenting with typical presentations and providing a specific test for MS in those with atypical presentations, thereby avoiding unnecessary costs associated with misdiagnosis. We will leverage the NAIMS Cooperative to conduct a multicenter study, based on an initial cross-sectional pilot study using the CVS criteria as a diagnostic biomarker for MS.

The CVS and PRL have emerged as specific and sensitive biomarkers for MS with pathologic specificity and are posed to improve diagnostic accuracy in MS. The CVS is a radiological sign that demonstrates perivenular demyelination that is specific for MS.39 PRL are a diagnostic biomarker of chronic active lesions, characterized by a core of demyelinated tissue surrounded by activated microglia with iron accumulation, making them visible on high-resolution T2*-weighted imaging.40 The definitions of both CVS and PRL have already been defined and operationalized as published by the North American Imaging in MS Cooperative (NAIMS) in two separate publications38,41 and will be incorporated into the next diagnostic criteria for MS.42 Analysis of the CAVS Pilot Study (funded by the Race to Erase MS foundation) showed that selecting up to 6 CVS+ lesions had a specificity of 98% for a diagnosis of MS,43 and definitive diagnostic performance of both the CVS and PRL is currently under way in the prospective CAVS-MS study to examine the diagnostic performance of the CVS in 420 participants who presented to 11 NAIMS sites for a diagnostic evaluation of MS with both typical and atypical presentations. This study is following patients who presented to MS Centers for a diagnostic evaluation of MS over the course of 24 months. CAVS-MS is also leveraging acquisition of the T2*-weighted segmented echo-planar imaging to extract phase images and test the diagnostic performance of PRLs.

In addition to the use of T2*-weighted images to improve the diagnosis of MS, the identification of PRL lesions in patients with MS may also serve as a prognostic marker of the disease. Studies have found that PRL are radiological biomarkers of chronic active lesions, occur despite the use of disease modifying treatment, and are associated with greater accumulation of disability.44 The slowly expanding lesion (SEL) is another proposed biomarker of chronic active lesion that employs a Jacobian determinant to identify lesions with concentric and constant growth over serial images.45 Current studies demonstrate an imperfect overlap between PRL and SEL,46 and comparative studies of these markers early in the disease are needed.47

The CAVS-MS study, therefore, is an ideal dataset on which to test both the diagnostic and prognostic properties of CVS and PRLS. However, 24-month follow-up may be insufficient time to detect new demyelinating events, especially in individuals with atypical presentations including radiologically isolated syndrome (RIS). 24 months may also be too short to detect worsening disability in those diagnosed with MS.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • multiple sclerosis
  • MS
  • MRI
  • central vein sign
  • CVS
  • Diagnostic biomarker
  • autoimmune disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be enrolled in and meet all inclusion criteria of the CAVS-MS study.
  • Must have participated in the CAVS-MS study and have completed month 24 visits.
  • Able to provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • to MRI studies; metal or metal implants incompatible with MRI
  • Inability to tolerate MRI due to claustrophobia or known excessive movement (e.g. tremor).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Confirmed diagnosis of MS at the end of the CAVS-MS study

    Diagnostic Test: MRI Contrast

  • Experimental
    Unconfirmed diagnosis of MS (at risk for MS) at the end of the CAVS-MS study

    Diagnostic Test: MRI Contrast

Interventions

  • Diagnostic testMRI Contrast

    The study will include an MRI

06

What researchers measure

Primary outcomes

  1. MRI Outcomes- CVS

    An MRI will be done at the Month 48 visit. Central veins will be counted and lesions will be considered CVS+ using specified criteria. CVS will be determined using Select6, Select3\* by already trained raters from the core CAVS-MS study and using automated lesion analysis.

    Time frame: Change assessed over 48 months. Scans done in the CAVS-MS core study (Baseline and Month 24) will be compared to scan done at Month 48.

  2. MRI Outcomes- PRL

    An MRI will be done at the Month 48 visit. Periventricular rim lesions (PRL) will be counted using specified criteria by already trained raters from the CAVS-MS core study and using automated lesion analysis. The automated lesions analysis will also determine lesion volume and RIM volume.

    Time frame: Change assessed over 48 months. Scans done in the CAVS-MS core study (Baseline and Month 24) will be compared to scan done at Month 48.

  3. Clinical Outcomes- Diagnosis of MS by 2017 Diagnostic Criteria

    Determination of a diagnosis of MS using the McDonald Criteria 2017 will be conducted by a central adjudication committee. McDonald diagnostic criteria for MS are clinical, radiographic, and laboratory criteria used in the diagnosis of multiple sclerosis. Members of the adjudication committee will separately review the clinical data, laboratory testing, and study MRIs of each participant at Month 48.

    Time frame: McDonald criteria will be reviewed at Month 48.

  4. Clinical Outcomes- EDSS

    The Expanded Disability Status Scale (EDSS) is a standardized assessment that will be used to measure the degree of disability due to MS using a 0-10 scale. 0 meaning no disability and 10 meaning death due to MS.

    Time frame: EDSS will be assessed at the Month 48 visit.

  5. Clinical Outcomes- Multiple Sclerosis Functional Composite (MSFC-4)

    The MSFC-4 is group of standardized assessments that are used to measure the degree of disability due to MS. The z-scores for the tests are averaged to create the final MSFC score. A higher score indicates better function. These assessments include: Timed 25 Foot Walk (lower extremity function) 9-Hole Peg Test (upper extremity function) Symbol Digit Modalities Test (processing speed) Low-Contrast Letter Acuity (visual function)

    Time frame: MSFC-4 will be assessed at the Month 48 visit.

07

Study locations

1 of 3 sites recruiting
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
    Not yet recruiting
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
    • Dawn Maniawski · ContactMANIAWD@ccf.org · 216 636-9196
    • Daniel Ontaneda, MD, PhD · Principal investigator
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
    • Russell Shinohara · Principal investigator
    • Matthew Schindler · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 14 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 20, 2026
StartActual
Oct 7, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07424027
Responsible party
Daniel Ontaneda, MD (Staff Neurologist, Mellen Center for Multiple Sclerosis, The Cleveland Clinic) — Principal investigator
First posted
Feb 20, 2026
Start date
Oct 7, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Meghan Kilbane
Contact
kilbanm@ccf.org
216-445-9845
Daniel Ontaneda, MD, PHD
principal investigator · The Cleveland Clinic
Pascal Sati, PHD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion